KDM5C and nonpapillary renal cell carcinoma: Given that advanced ccRCC tumours are treated with immune checkpoint therapies, it will be important to further characterise the consequences of loss of the Y chromosome and mutation of KDM5C in the context of male ccRCC tumour evolution and tumour cell interactions with the immune system to determine if these different types of genetic alterations may shape the tumour immune microenvironment.